WO2017105881A8 - Deuterated compounds for treating pain - Google Patents

Deuterated compounds for treating pain Download PDF

Info

Publication number
WO2017105881A8
WO2017105881A8 PCT/US2016/064812 US2016064812W WO2017105881A8 WO 2017105881 A8 WO2017105881 A8 WO 2017105881A8 US 2016064812 W US2016064812 W US 2016064812W WO 2017105881 A8 WO2017105881 A8 WO 2017105881A8
Authority
WO
WIPO (PCT)
Prior art keywords
treating pain
deuterated compounds
deuterated
compounds
disorder
Prior art date
Application number
PCT/US2016/064812
Other languages
French (fr)
Other versions
WO2017105881A1 (en
Inventor
Changfu CHENG
Chaoran HUANG
Original Assignee
NeuForm Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NeuForm Pharmaceuticals, Inc. filed Critical NeuForm Pharmaceuticals, Inc.
Publication of WO2017105881A1 publication Critical patent/WO2017105881A1/en
Publication of WO2017105881A8 publication Critical patent/WO2017105881A8/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The invention provides novel chemical compounds useful for treating pain or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof.
PCT/US2016/064812 2015-12-15 2016-12-02 Deuterated compounds for treating pain WO2017105881A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562267700P 2015-12-15 2015-12-15
US62/267,700 2015-12-15

Publications (2)

Publication Number Publication Date
WO2017105881A1 WO2017105881A1 (en) 2017-06-22
WO2017105881A8 true WO2017105881A8 (en) 2017-12-14

Family

ID=59057413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/064812 WO2017105881A1 (en) 2015-12-15 2016-12-02 Deuterated compounds for treating pain

Country Status (1)

Country Link
WO (1) WO2017105881A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019503351A (en) * 2015-12-17 2019-02-07 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． Combination of opioid receptor ligand and cytochrome P450 inhibitor
WO2018006077A1 (en) * 2016-07-01 2018-01-04 NeuForm Pharmaceuticals, Inc. Deuterated compounds for treating pain
WO2019158634A1 (en) * 2018-02-16 2019-08-22 Esteve Pharmaceuticals, S.A. Deuterated derivatives of 9-(2,5-difluorophenethyl)-4-ethyl-2-methyl-1-oxa-4,9-diazaspiro[5.5]undecan-3-one
CN116075505A (en) * 2021-08-31 2023-05-05 天地恒一制药股份有限公司 Opioid receptor agonist, preparation method and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10123129A1 (en) * 2001-05-02 2002-11-14 Berolina Drug Dev Ab Svedala Deuterated 3-piperidinopropiophenones and medicinal products containing these compounds
KR101991327B1 (en) * 2011-03-23 2019-06-20 트레베나, 인코포레이티드. Opioid Receptor Ligands and Methods of Using and Making Same

Also Published As

Publication number Publication date
WO2017105881A1 (en) 2017-06-22

Similar Documents

Publication Publication Date Title
IL264049A (en) Compounds, compositions, and methods for the treatment of disease
WO2017117070A8 (en) Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof
IL264156A (en) Compounds, compositions, and methods for the treatment of disease
EP3675859A4 (en) Compounds, compositions, and methods for the treatment of disease
IL269599B1 (en) 11,13-modified saxitoxins for the treatment of pain
WO2017106346A3 (en) Human immunodeficiency virus neutralizing antibodies
WO2016149401A3 (en) Piperazine carbamates and methods of making and using same
WO2015179559A3 (en) Pyrazole compounds and methods of making and using same
IL258471A (en) 11,13-modified saxitoxins for the treatment of pain
EP3778605A3 (en) Lrrk2 inhibitors and methods of making and using the same
WO2015001504A3 (en) Antibody formulations and methods
EA201790766A1 (en) NEW METHILPIPERIDINE CONNECTIONS SUITABLE FOR INHIBITING MICROSOMAL PROSTAGLANDIN-E2-SYNTHASE 1
SA518400356B1 (en) Arginase inhibitors and their therapeutic applications
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
IL285782A (en) Compounds, compositions, and methods for the treatment of disease
EP3411504A4 (en) Anti-tnf antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes
MX2016012574A (en) Substituted heteroaryl compounds and methods of use.
PH12019501690A1 (en) Pyrimidine compound and pharmaceutical use thereof
EP3802539C0 (en) Tetrahydro-1h-pyrazino[2,1-a]isoindolylquinoline compounds for the treatment of autoimmune disease
WO2017136450A3 (en) Compounds and methods of treating rna-mediated diseases
WO2015015378A3 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
WO2018023072A3 (en) Compounds and compositions and uses thereof
WO2018067520A3 (en) Therapeutic agents and methods:
WO2017105881A8 (en) Deuterated compounds for treating pain
WO2016057683A3 (en) Novel anti-nodal antibodies and methods of using same

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16876381

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16876381

Country of ref document: EP

Kind code of ref document: A1